ID
20217
Descrição
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.
Palavras-chave
Versões (2)
- 30/01/2017 30/01/2017 -
- 14/02/2017 14/02/2017 -
Transferido a
14 de fevereiro de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Concomitant Non-Drug Therapy CRFs Multiple Sclerosis Tysabri NCT00027300
Concomitant Non-Drug Therapy CRFs Multiple Sclerosis Tysabri NCT00027300
Similar models
Concomitant Non-Drug Therapy CRFs Multiple Sclerosis Tysabri NCT00027300
C1707479 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])